ArticleOncoimmunology2015
Natural killer cell mediated immunosurveillance of pediatric neuroblastoma.
Article in Oncoimmunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 47 citations in OpenAlex.
- Breakthrough of solid tumor treatment: CAR-NK immunotherapy.Cell death discovery · 2024Review
- Dysregulation of DNAM-1-Mediated NK Cell Anti-Cancer Responses in the Tumor Microenvironment.Cancers · 2023Review
- Immune profile of primary and recurrent epithelial ovarian cancer cases indicates immune suppression, a major cause of progression and relapse of ovarian cancer.Journal of ovarian research · 2023Article
- Investigating the susceptibility of treatment-resistant oesophageal tumours to natural killer cell-mediated responses.Clinical and experimental medicine · 2023Article
- Investigating the Effects of Olaparib on the Susceptibility of Glioblastoma Multiforme Tumour Cells to Natural Killer Cell-Mediated Responses.Pharmaceutics · 2023Article
- Natural killer cell immunotherapy in glioblastoma.Discover oncology · 2022Review
- Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer.Clinical and experimental immunology · 2022Review
- Asymptomatic incidental neuroblastoma in a patient with SH2D1A deficiency.Pediatric blood & cancer · 2022Article
- Role of the ITAM-Bearing Receptors Expressed by Natural Killer Cells in Cancer.Frontiers in immunology · 2022Review
- Cell surface vimentin-positive circulating tumor cell-based relapse prediction in a long-term longitudinal study of postremission neuroblastoma patients.International journal of cancer · 2020Article
- Nanoformulation of CCL21 greatly increases its effectiveness as an immunotherapy for neuroblastoma.Journal of controlled release : official journal of the Controlled Release Society · 2020Article
- Article
- Antimetastatic effects of thalidomide by inducing the functional maturation of peripheral natural killer cells.Cancer science · 2020Article
- NK cells for cancer immunotherapy.Nature reviews. Drug discovery · 2020Review
- The Natural Cytotoxicity Receptors in Health and Disease.Frontiers in immunology · 2019Review
- NK Cell-Based Immunotherapy in Cancer Metastasis.Cancers · 2018Review
- The B7 Family Member B7-H6: a New Bane of Tumor.Pathology oncology research : POR · 2018Review
- Article
- Targeting Cancer Stem Cells with Natural Killer Cell Immunotherapy.Expert opinion on biological therapy · 2017Review
- Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.Oncoimmunology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Until recently, the pathophysiological impact of natural killer (NK) lymphocytes has been largely elusive. Capitalizing on our previous discovery that NK cells mediate immunosurveillance against gastrointestinal stromal tumors (GISTs), we have now investigated the potential influence of immunostimulatory and immunosuppressive isoforms of the NK receptor NKp30 on the fate of infants with neuroblastoma. In three independent cohorts of high-risk neuroblastoma, we observed a similar prognostic impact of the ratio of immunostimulatory vs. immunosuppressive NKp30 isoforms. Patients with high-risk neuroblastoma that are in remission after induction chemotherapy have a higher risk of relapse if their circulating and bone marrow NK cells express the preponderantly immunosuppressive NKp30 C isoform, as determined by a robust RT-PCR-based assay. We also found that neuroblastoma cells express the NKp30 ligand B7-H6, which can be shed from the tumor cells. Elevated soluble B7-H6 levels contained in patient sera inhibited NK functions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.